Phase 2 CADENCE Trial Confirms Proof-of-Concept for WINREVAIR™ in CpcPH-HFpEF Patients
Phase 2 CADENCE Trial Shows Positive Results, Establishing WINREVAIR™ as a Proof-of-Concept Therapy in CpcPH and HFpEF Merck & Co.—known as MSD outside the United States and Canada—has unveiled comprehensive…
Bepirovirsen Gains European Medicines Agency Review as a Potential First-in-Class Therapy for Chronic Hepatitis B
Bepirovirsen advances to regulatory review by the European Medicines Agency as a promising first-in-class therapy for chronic hepatitis B GSK plc has announced a significant regulatory milestone as the European…
Novartis to Acquire Excellergy, Inc., Strengthening Allergy Leadership with Next-Generation Anti-IgE Innovation
Novartis Agrees to Acquire Excellergy, Inc. to Strengthen Allergy Leadership with Next-Generation Anti-IgE Innovation Novartis has announced a strategic agreement to acquire Excellergy, a privately held biotechnology company focused on…
AbbVie to Present New Data Advancing Care in Immune-Mediated Skin Diseases at AAD 2026
AbbVie to Present New Clinical and Real-World Evidence Advancing Care Standards in Immune-Mediated Skin Diseases at the AAD Annual Meeting 2026 AbbVie has announced a comprehensive slate of new research…
Eli Lilly and Company’s EBGLYSS Shows Up to Four Years of Sustained Control in Atopic Dermatitis
Eli Lilly and Company Reports Up to Four Years of Sustained Disease Control with EBGLYSS (lebrikizumab-lbkz) in Moderate-to-Severe Atopic Dermatitis Eli Lilly and Company has unveiled compelling new long-term data…
Real Time Medical Systems to Showcase How Live Data Enhances Clinical Standards and Survey Readiness at PALTC26
Real Time Medical Systems to Showcase How Live Data Enhances Clinical Standards and Survey Readiness at PALTC26 Real Time Medical Systems, widely recognized as a leading provider of post-acute care…
Sensus Healthcare Files Breach of Contract Lawsuit Against SkinCure Oncology
Sensus Healthcare Files Breach of Contract Lawsuit Against SkinCure Oncology Sensus Healthcare, Inc., a developer of non-invasive and minimally invasive technologies for the treatment of both oncological and non-oncological skin…
LEO Pharma Highlights Long-Term SPEVIGO® Data in GPP at AAD 2026
LEO Pharma Presents New Long-Term Data for SPEVIGO® (spesolimab-sbzo) in Adults with Generalized Pustular Psoriasis at AAD 2026 LEO Pharma A/S has announced new long-term clinical data supporting the use…
Banner|Aetna Joins Community in Supporting the 2026 Phoenix Heart Walk
Banner|Aetna Engages Community at the 2026 Phoenix Heart Walk Banner|Aetna, an integrated health plan formed through a collaboration between Banner Health and CVS Health through its Aetna business, is actively…
Enveric Biosciences Announces Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update
Enveric Biosciences Announces Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Enveric Biosciences, a biotechnology company focused on developing next-generation neuroplastogenic small molecules for psychiatric and neurological disorders,…
Angelalign Technology Reports 2025 Results, Highlighting Clinical Excellence as a Key Driver of Global Expansion
Angelalign Technology Reports 2025 Results, Highlighting Clinical Excellence as a Key Driver of Global Expansion Angelalign Technology Inc. (6699.HK) has announced its financial results for the fiscal year 2025, reporting…
Lantern Pharma Reaffirms Panna Sharma as President and CEO, Addresses Misleading Third-Party Report
Lantern Pharma Reaffirms Panna Sharma’s Ongoing Role as President and CEO; Warns Investors of Misleading Third-Party Report Lantern Pharma Inc., an AI-driven oncology company focused on transforming cancer drug development…